SUMMARY In a retrospective follow-up we compared the incidence of malignancies in patients with rheumatoid arthritis treated with cyclophosphamide with that in another group of patients with rheumatoid arthritis and also with the incidence of malignancies in the general population. Among 81 patients treated with cyclophosphamide in the past decade 15 malignancies occurred. This was 441 times the expected number obtained from a closely matched control group of patients with rheumatoid arthritis not treated with cytotoxic drugs (95 % confidence interval 1P5 to 19 0), and 3 7 times the expected number calculated from general population rates (95 % confidence interval 2*1 to 5.9). The increase in haematological and lymphoreticular malignancies was specially notable. The data also indicate that the development of malignancies after the start of cyclophosphamide therapy necessitates a certain induction time and that it is to some extent dose-dependent.
Following the publications by Fosdick et al. 1 2 we started to treat rheumatoid arthritis (RA) patients with cyclophosphamide (CP) in the Arnhem Municipal Hospital in 1969. As elsewhere'-12 our clinical results were encouraging.
In the 1970s, however, a disquieting number of case reports and restrospective follow-up studies indicated an increased occurrence of neoplasms, particularly of the haematological and lymphoreticular systems, due to cytotoxic therapy. This complication was first reported in transplant patients 13 15 and later in various diseases, among them RA. 8 6-26 We decided to undertake this retrospective controlled study to get a better insight in the real occurrence of the malignancies and, in particular, the haematological and lymphoreticular malignancies. We had in fact been struck by a succession of this type of malignancies not only in patients treated with CP but also in patients who had never been treated with cytotoxic drugs. Moreover, both an increase and a decrease of malignancies have been reported in RA patients. [27] [28] [29] [30] [31] [32] [33] [34] [35] [36] [37] The aim of this study was to compare the incidence of malignancies in our RA patients treated with CP with that in a comparable RA control group. In addiAccepted for publication 22 June 1982. Correspondence to Dr J. W. Boersma, Department of Rheumatology, Amhem Municipal Hospital, Wagnerlaan 55, 6815 AD Arnhem, The Netherlands.
tion we compared this incidence with the cancer rates of the general population.
Patients and methods
The cyclophosphamide group consisted of 81 RA patients. Twenty-eight of them were in a small prospective follow-up study that 39 Division of the number of malignancies observed in the CP group by the number expected yields the standardised morbidity ratio. 40 To calculate the 95 % confidence interval of the observed-to-expected (O/E) ratio when the expected number is calculated out of general population rates, one can make use of the large sample assumption that the observed number is a realisation of a Poisson variable, and that the expected number has a neglegible variance. 40 The exact 95 % confidence limits of the observed number can then be found in standard tables of the confidence limits of Poisson variables4"; the 95% confidence limits of the O/E ratio are then obtained by the division of these confidence limits of the observed number by the expected number. In contrast, when the expected number is calculated from the malignancy rates in the RA control group, the assumption of a negligibly small variance cannot be made. In the calculation of the confidence limits of the O/E ratio we now have to take into account both the variability of the observed and that of the expected number. This was accomplished by a logarithmic transformation of the O/E ratio. Again assuming that the observed and the expected numbers are realisations of a Poisson variable, we can calculate the 95 % confidence limits of ln(O/E) by the use of general approximate formulae for the variance of transformed random variables. 40 The 95 % confidence limits of the O/E ratio itself are then obtained as the exponential of the confidence limits of ln(O/E). The main use of the confidence interval is to give the reader an impression of the statistical uncertainty of the observed-to-expected ratio. The confidence interval of the ratio calculated with the RA control group will inevitably be wider than the confidence interval of the ratio calculated with the general population rates.
We also plotted the occurrence of malignancies in each year of follow-up as a percentage of the number still under observation. This graphical display was intended to illustrate a time-occurrence relationship. Finally we calculated the total dose received by the persons developing malignancies and by the persons who did not develop a malignancy. To assess the statistical significance of the difference in dose and duration of therapy between the CP patients who developed a malignancy and those that did not we used the t test for the difference between 2 means.
Results
The characteristics of the CP-treated patients with RA and of the matched RA control group are shown in Table 1 . The duration of follow-up in the control group was somewhat longer owing to the longer survival of these patients.
An enumeration of the malignancies that occurred in the CP-treated patients with RA and in the matched RA control group is given in Table 2 .
The observed and the expected number of malignancies in the CP-treated patients with RA, the observed/expected ratio, and its confidence interval are given in Table 3 . The observed/expected ratios all differ significantly from unity at the 5 % level.
The observed and expected number of haematolymphoreticular malignancies in CP-treated patients with RA, the observed/expected ratio, and its confidence interval are given in Table 4 . In this table we contrast the observed number in the CP group with the expected number derived from the general population rates for the Netherlands. A calculation of the 19 12 Joint surgery (number) 4 16 Sero-positivity (number) 69 52 Fig. 1 . The number of malignancies is expressed as a percentage of the number of patients observed in each follow-up year group.
The CP dose received and duration of CP therapy are given in Table 5 . Although the ranges are wide, there is a clear gradient between the patients who developed a malignancy and those who did not.
Discussion
Our findings indicate an approximately 4-fold increase in the overall incidence of malignancies among RA patients treated with CP. This 4-fold increase is found in comparison with RA patients that had never been treated with cytotoxic drugs as well as in comparison with the general population. Most impressive was the increase in the haematological and lymphoreticular malignancies. The latter are estimated to be increased about 15-fold in comparison with the general population.
When a control group is chosen to estimate the expected number of malignancies, it is obvious that the most valid control group would consist of RA patients of similar age and sex and with a disease course of similar severity. We have tried to achieve this by taking into the control group only RA patients who had been treated as inpatients, and by matching them with the CP group by age, sex, and date of admission to hospital. Thus the RA control patients were all patients with severe disease who required hospitalisation, either for the start of a new drug therapy or for evaluation of joint surgery. We have tried to assess the comparability of the 2 groups by the information given in Table 1 . Whether one can ever guarantee complete comparability when the selection is not randomised is a matter of debate. In principle one could argue that patients who have once been selected for CP treatment will never be exactly like another group of patients who have not (yet) been selected for that form of treatment, whatever some parameters for disease activity show. In consequence one could maintain that it is the disease course of this selected group of CP-treated patients, rather than the therapy they receive, which is responsible for their higher malignancy rates. The likelihood of the latter explanation namely, that apresumably small -difference in disease course could cause a many-fold increase in tumour occurrence, is questionable. However, it may be noted that one of the patients in the CP-treated group who developed a basal cell skin carcinoma suffered also from psoriatic erythrodermia, and that another was described by the attending dermatologist as a victim of a 'tropical skin'. As for the higher lung cancer rates in the CPtreated group, we lack comparative information about the smoking histories of the 2 groups.
The close matching requirements that we had imposed on our RA control group made it impossible to find more than one RA control for each CP patient. The To corroborate further the causal nature of the association between the increased occurrence of malignancies and CP therapy we used 2 other descriptions of the CP-treated patients. First, the plot of the percentage occurrence of malignancies in each year of follow-up (Fig. 1) shows a rise up to a 7 to 9% annual tumour occurrence in 3 consecutive years. In the general population one would expect a yearly occurrence that would be only about 0.5 %. The descending part of the peak in Fig. 1 concerns estimates based on small numbers only, which entails great follow-up statistical uncertainty. Nevertheless the 3 very high occurrences after 7, 8, and 9 years of follow-up fit the idea of a tumour induction that shows itself after a certain time lag, which corresponds to general concepts of carcinogenesis. A contrary finding, an even spread of the tumour occurrence over time, would have rendered the causality of the association less likely. Secondly, the total CP dose received and the duration of therapy were higher in those patients who developed a malignancy. The difference was of borderline statistical significance only for the dosage.
Our investigation was started from the hypothesis that much of the alarm about cytotoxic therapy was due to inadequate control groups. Our findings concerning malignancies associated with CP confirm most of the recent reports about alkylating agents.48-52 By contrast, some workers53-55 did not report such an association in their studies. Nevertheless, at present our policy is to reserve CP, however beneficial, for the fully informed patient in whom all other therapy failed and who clearly announces that a life with pain and disablement is not worthwhile living.
